Ascentage Pharma

Leukaemia
#Ascentage Pharma #Blood cancer #China #Haematology #Oncology

First Bcl-2 inhibitor approved in China for CLL/SLL

Ascentage Pharma’s Bcl-2 selective inhibitor lisaftoclax (APG-2575) has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL).  It is approved in patients who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. … Read More

#News #Regulatory

Chinese flag
#Ascentage Pharma #Blood cancer #China #Haematology #Oncology

Ascentage celebrates inclusion in Chinese oncology guidelines

Two of Ascentage Pharma’s drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines.   Lisaftoclax (APG-2575), an investigational novel oral Bcl-2 selective inhibitor, received its first recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies.  This makes… Read More

#News

Nasdaq stock market
#Ascentage Pharma #Haematology #Market reporting #Oncology

Hong Kong based Ascentage Pharma lists on Nasdaq

Ascentage Pharma has listed on the Nasdaq Global Market, becoming the first 18A company to achieve a dual listing on the US stock market.   Ascentage Pharma offered 7,325,000 American depositary shares (ADS) at $17.25 per ADS. The proceeds from the offering are expected to be approximately $126.4 million.  The company… Read More

#Business & Investment #News